Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904

Journal of Clinical Oncology

Volumn 27, Issue 33, 2009, Pages 5506-5512

  Kulke, Matthew H ^a   Tempero, Margaret A ^a   Niedzwiecki, Donna ^a   Hollis, Donna R ^a   Kindler, Hedy L ^a   Cusnir, Michael ^a   Enzinger, Peter C ^a   Gorsch, Stefan M ^a   Goldberg, Richard M ^a   Mayer, Robert J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CISPLATIN; DEXAMETHASONE; DOCETAXEL; GEMCITABINE; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE; TAXOID;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; EDEMA; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERGLYCEMIA; INFECTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; VOMITING; ADENOCARCINOMA; CANCER STAGING; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; PATHOLOGY; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME; UNITED STATES;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; CONFIDENCE INTERVALS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; UNITED STATES;

EID: 73949094909     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.1309     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008
2. Burris H, Moore M, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
3. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966, 2007
4. Cunningham D, Chau I, Stocken D, et al: Phase III randomised comparison of gemcitabine with gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Eur J Cancer 3:4, 2005 (suppl)
5. Herrmann R, Bodoky G, Ruhstaller T, et al: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Res and the Central European Cooperative Oncology Group. J Clin Oncol 25:2212-2217, 2007
6. Lenzi R, Yalcin S, Evans DB, et al: Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. Cancer Invest 20:464-472, 2002
7. Androulakis N, Kourousis C, Dimopoulos MA, et al: Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: A multicenter phase II study. J Clin Oncol 17:1779-1785, 1999
8. Wagener DJ, Verdonk HE, Dirix LY, et al: Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC Early Clinical Trials Group study. Ann Oncol 6:129-132, 1995
9. Rocha Lima C, Savarese D, Bruckner H, et al: Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 20:1182-1191, 2002
10. Jacobs AD, Otero H, Picozzi VJ Jr, et al: Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma. Cancer Invest 22:505-514, 2004
11. Heinemann V, Wilke H, Mergenthaler HG, et al: Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 11:1399-1403, 2000
12. Tempero M, Plunkett W, Ruiz Van Haperen V, et al: Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402-3408, 2003
13. Veltkamp SA, Beijnen JH, Schellens JH: Prolonged versus standard gemcitabine infusion: Translation of molecular pharmacology to new treatment strategy. Oncologist 13:261-276, 2008
14. Heinemann V, Quietzsch D, Gieseler F, et al: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24:3946-3952, 2006
15. Poplin E, Levy D, Berlin J, et al: Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed dose rate infusion versus gemcitabine + oxaliplatin in patients with advanced pancreatic cancer. J Clin Oncol 24:180s, 2006 (suppl; abstr LBA4004)
16. Rocha Lima CM, Green MR, Rotche R, et al: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776-3783, 2004
17. Stathopoulos GP, Syrigos K, Aravantinos G, et al: A multicenter phase III trial comparing irinotecangemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 95:587-592, 2006
18. Oettle H, Richards D, Ramanathan RK, et al: A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16:1639-1645, 2005
19. Louvet C, Labianca R, Hammel P, et al: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509-3516, 2005
20. Heinemann V, Labianca R, Hinke A, et al: Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: Pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol 18:1652-1659, 2007
21. Heinemann V, Boeck S, Hinke A, et al: Metaanalysis of randomized trials: Evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 8:82, 2008
22. Sultana A, Smith CT, Cunningham D, et al: Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25:2607-2615, 2007